1. Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines.
- Author
-
Weinberg, Adriana, Schmid, D Scott, Leung, Jessica, Johnson, Michael J, Miao, Congrong, and Levin, Myron J
- Subjects
- *
HERPES zoster vaccines , *ANTIBODY formation , *VACCINE effectiveness , *HERPES zoster , *CELLULAR immunity - Abstract
Background Protection against herpes zoster is primarily conferred by cell-mediated immunity. However, anti–varicella-zoster virus (VZV) glycoprotein (anti-gp) antibody responses to zoster vaccine live (ZVL) are correlated with protection, suggesting a potential protective role for antibody. Detailed studies of antibody responses to the recombinant zoster vaccine (RZV) are provided. Methods We compared enzyme-linked immunosorbent assay–measured anti–VZV glycoproteins (anti-gp) and glycoprotein E (anti-gE) antibody levels and avidity in 159 participants randomized to RZV (n = 80) or ZVL (n = 79) recipients over 5 years after vaccination and identified predictors of antibody persistence. Results The comparison between vaccine groups showed higher anti-gE and anti-gp antibody levels after RZV than after ZVL over the 5-year study duration. RZV recipients also had higher anti-gE avidity for 5 years and higher anti-gp avidity in the first year after vaccination. Compared with prevaccination levels, RZV recipients maintained higher levels of anti-gE antibodies and avidity for 5 years, whereas ZVL recipients only maintained higher anti-gE avidity. Anti-gp antibody levels and avidity decreased to prevaccination levels or below beyond 1 year after vaccination in both groups. Independent predictors of persistence of antibody levels and avidity included vaccine type, prevaccination and peak antibody levels and avidity, prevaccination and peak cell-mediated immunity, and age. Sex or prior ZVL administration did not affect persistence. Conclusions Antibody responses and avidity were higher and more persistent in RZV than in ZVL recipients. The effect of age on antibody persistence in RZV recipients is novel. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF